Immunopotentiators in modern vaccines /
Saved in:
| Edition: | Second edition. |
|---|---|
| Imprint: | Amsterdam : Academic Press, [2017] ©2017 |
| Description: | 1 online resource (xvii, 490 pages) : illustrations |
| Language: | English |
| Subject: | |
| Format: | E-Resource Book |
| URL for this record: | http://pi.lib.uchicago.edu/1001/cat/bib/11268948 |
MARC
| LEADER | 00000cam a2200000Ii 4500 | ||
|---|---|---|---|
| 001 | 11268948 | ||
| 005 | 20180526095402.6 | ||
| 006 | m o d | ||
| 007 | cr mn||||||||| | ||
| 008 | 161113t20172017ne a ob 001 0 eng d | ||
| 019 | |a 962325449 |a 965135176 | ||
| 020 | |a 9780128040195 |q (electronic bk.) | ||
| 020 | |a 012804019X |q (electronic bk.) | ||
| 020 | |a 9780128040959 |q (epub) | ||
| 020 | |a 0128040955 |q (epub) | ||
| 020 | |z 0120884038 | ||
| 020 | |z 0080457215 | ||
| 020 | |z 661063047X | ||
| 020 | |z 1280630477 | ||
| 035 | |a (OCoLC)963184312 |z (OCoLC)962325449 |z (OCoLC)965135176 | ||
| 037 | |a 9780128040959 |b Ingram Content Group | ||
| 040 | |a NLE |b eng |e rda |c NLE |d YDX |d OPELS |d OCLCF |d UPM |d OTZ |d GZM |d MERER |d OCLCQ |d OSU |d IDEBK |d COO |d CASUM |d OCLCO |d OCLCQ |d DKU | ||
| 049 | |a MAIN | ||
| 050 | 4 | |a QR187.3 |b .I56 2006eb | |
| 060 | 0 | 0 | |a 2017 B-625 |
| 060 | 1 | 0 | |a QW 805 |
| 245 | 0 | 0 | |a Immunopotentiators in modern vaccines / |c Virgil Schijns, Wageningen University, Wageningen, The Netherlands ; Derek O'Hagan, GSK Vaccines, Rockville MD, United States. |
| 250 | |a Second edition. | ||
| 264 | 1 | |a Amsterdam : |b Academic Press, |c [2017] | |
| 264 | 4 | |c ©2017 | |
| 300 | |a 1 online resource (xvii, 490 pages) : |b illustrations | ||
| 336 | |a text |b txt |2 rdacontent |0 http://id.loc.gov/vocabulary/contentTypes/txt | ||
| 337 | |a computer |b c |2 rdamedia |0 http://id.loc.gov/vocabulary/mediaTypes/c | ||
| 338 | |a online resource |b cr |2 rdacarrier |0 http://id.loc.gov/vocabulary/carriers/cr | ||
| 520 | |a Immunopotentiators in Modern Vaccines, Second Edition, provides in-depth insights and overviews of the most successful adjuvants, those that have been included in licensed products, also covering the most promising technologies that have emerged in recent years. In contrast to existing books on the subject, the chapters here provide summaries of key data on the mechanisms of action of the individual vaccine adjuvants. In addition, the book covers key aspects of how the technologies might be further developed and what might be their limitations, while also giving an overview of what made the most advanced adjuvant technologies successful. Provides contributions from leading international authorities in the field; features immunopotentiators classified by function, with well-illustrated, informative figures presenting the interaction between the immunopotentiators and the host immune system; lists advantages and potential hurdles for achieving a practical application for each specific immunopotentiator; offers US FDA perspectives which highlight how future adjuvants will be approved for new generation vaccines. | ||
| 504 | |a Includes bibliographical references and index. | ||
| 505 | 0 | |a Vaccine adjuvants' mode of action: unraveling "the Immunologist's Dirty Little Secret" / V.E.J.C. Schijns -- The role of inflammasomes in adjuvant-driven humoral and cellular immune responses / N. Muñoz-Wolf, S. McCluskey, E.C. Lavelle -- Dendritic cells as targets of vaccines and adjuvants / M.M. Strioga, N.T. Dobrovolskiene -- Host-derived cytokines and chemokines as vaccine adjuvants / W.G.J. Degen, V.E.J.C. Schijns -- Discovery of immune potentiators as vaccine adjuvants / C. Buonsanti, U. D'oro -- Current status of toll-like receptor 4 ligant vaccine adjuvants / C.B. Fox, D. Carter, R.M. Kramer, A.M. Beckmann, S.G. Reed -- Flagellins as adjuvants of vaccines / M. Rumbo, C. Carnoy, J.C. Sirard -- Toll-like receptor 7 and 8 agonists for vaccine adjuvant use / M.A. Tomai, J.P. Vasilakos -- CpG Oligodeoxynucleotides as adjuvants for clinical use / H. Shirota, D.M. Klinman -- Advax adjuvant: a potent and safe immunopotentiator composed of delta inulin / N. Petroski -- Natural vaccine adjuvants and immunopotentiators derived from plants, fungi, marine organisms, and insects / N. Woods, K. Niwasbutra, R. Acevedo, J. Igoli, N.A. Altwaijry, J. Tusiimire, A.I. Gray, D.G. Watson, V.A. Ferro -- Polymeric particles as vaccine delivery systems / P. Malyala, D.T. O'Hagen -- MF59: a safe and potent adjuvant for human use / S. Kommareddy, M. Singh, D.T. O'Hagan -- The development of the adjuvant system AS01: a combination of two immunostimulants MPL and QS-21 in liposomes / A.M. Didierlaurent, A. Berger, T.C. Heineman, V. Henderickx, F. Tavares Da Silva, J. Vekemans, G. Voss, N. Garçon -- Development and evaluation of AS04, a novel and improved adjuvant system containing 3-0-Desacyl-4'- monophosphoryl lipid A and aluminum salt / N. Garçon, F. Tavares Da Silva -- ISCOMATRIX adjuvant in the development of prophylactic and therapeutic vaccines / A.B. Morelli, E. Maraskovsky -- Development and evaluation of CAF01 / D. Christensen -- Mineral adjuvants / E.B. Lindblad, L. Duroux -- Toxin-based mucosal adjuvants / A.M. Harandi, N. Lycke -- Adjuvants for skin vaccination / I. Skountzou, N. Brock, N. Lelutiu, R.W. Compans -- Vaccination to treat noninfectious diseases: surveying the opportunities / M.F. Bachmann, M. Vogel -- A framework for evaluating nonclinical safety of novel adjuvants and adjuvanted preventive vaccines / P.E. Boucher. | |
| 506 | |a Owing to Legal Deposit regulations this resource may only be accessed from within National Library of Scotland. For more information contact enquiries@nls.uk. |5 StEdNL | ||
| 588 | |a Description based on print version record. | ||
| 650 | 0 | |a Immunological adjuvants. |0 http://id.loc.gov/authorities/subjects/sh85000895 | |
| 650 | 0 | |a Immune response |x Regulation. |0 http://id.loc.gov/authorities/subjects/sh85064538 | |
| 650 | 0 | |a Vaccines. |0 http://id.loc.gov/authorities/subjects/sh85141718 | |
| 650 | 7 | |a Immune response |x Regulation. |2 fast |0 http://id.worldcat.org/fast/fst00967872 | |
| 650 | 7 | |a Immunological adjuvants. |2 fast |0 http://id.worldcat.org/fast/fst00967992 | |
| 650 | 7 | |a Vaccines. |2 fast |0 http://id.worldcat.org/fast/fst01163573 | |
| 650 | 1 | 2 | |a Vaccines |x immunology. |0 http://id.nlm.nih.gov/mesh/D014612Q000276 |
| 650 | 2 | 2 | |a Adjuvants, Immunocologic. |
| 650 | 2 | 2 | |a Drug Delivery Systems. |0 http://id.nlm.nih.gov/mesh/D016503 |
| 650 | 2 | 2 | |a Immunotherapy. |0 http://id.nlm.nih.gov/mesh/D007167 |
| 655 | 0 | |a Electronic books. |0 http://id.loc.gov/authorities/subjects/sh93007047 | |
| 655 | 4 | |a Electronic books. | |
| 700 | 1 | |a Schijns, Virgil, |e editor. | |
| 700 | 1 | |a O'Hagan, Derek, |e editor. | |
| 776 | 0 | 8 | |i Print version: |t Immunopotentiators in modern vaccines. |b Second Edition. |d Amsterdam : Elsevier/Academic Press, [2017] |z 012804019X |w (DLC) 2016499638 |w (OCoLC)954224118 |
| 903 | |a HeVa | ||
| 929 | |a oclccm | ||
| 999 | f | f | |i 953c30ce-4e30-5d62-9dfc-0dee0d691cd4 |s 0f0cfdfc-5d45-5d53-a73d-ccaf3c09c798 |
| 928 | |t Library of Congress classification |a QR187.3 .I56 2006eb |l Online |c UC-FullText |u https://www.sciencedirect.com/science/book/9780128040195 |z Elsevier |g ebooks |i 10979721 | ||